Instanosis

Executive Summary

Instanosis is a US-based diagnostics company founded in 2021, with operations in San Diego, CA, and King of Prussia, PA. The company focuses on developing and commercializing ultra-sensitive, point-of-care diagnostic tests, primarily for rapid drug detection. Its mission is to bring high-performance, hospital-grade diagnostics directly to the patient's side, empowering frontline responders and healthcare systems. By leveraging advanced sensing technologies, Instanosis aims to deliver results in minutes with lab-level accuracy, addressing critical needs in emergency medicine, addiction treatment, and law enforcement. The company targets a market that demands speed, portability, and reliability, especially for opioid and fentanyl detection, where current solutions are either too slow or lack sensitivity. Instanosis's platform could reduce turnaround times from hours to minutes, enabling faster clinical decisions and potentially saving lives in overdose situations. Despite being in a competitive landscape with players like Abbott and Roche, Instanosis differentiates through its focus on drug detection and its ultra-sensitive approach. The company has not disclosed funding rounds or revenue, suggesting it is still in early development or pre-commercial stage. Key upcoming milestones include potential FDA clearance for its lead test, partnerships with emergency medical services or correctional facilities, and a Series A funding round to scale operations. The success of Instanosis will depend on regulatory approvals, clinical validation, and adoption by frontline users. Given the urgent need for rapid drug detection tools, the company has significant growth potential if it executes well.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) clearance for lead drug detection test40% success
• Q1 2027Partnership with a major EMS or public health system30% success
• Q3 2026Series A funding round closure60% success